Discover investment opportunities in Top 10 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $2 using our Smart AI Filter.
6 stocks found for "Top 10 Stocks Under $2"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.40 Risk measure | ±59.3% Price volatility | -45.5 Valuation | 0.00% Annual yield | |||
1.56 Risk measure | ±82.7% Price volatility | -121.0 Valuation | 0.00% Annual yield | |||
2.07 Risk measure | ±100.0% Price volatility | -4.2 Valuation | 0.00% Annual yield | |||
0.83 Risk measure | ±61.9% Price volatility | -3.1 Valuation | 0.00% Annual yield | |||
0.71 Risk measure | ±56.0% Price volatility | -26.5 Valuation | 0.00% Annual yield | |||
0.25 Risk measure | ±49.2% Price volatility | 8.0 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreOn Friday, a day after Israel launched 'Operation Rising Lion' targeting over 100 Iranian nuclear and military sites, Iran retaliated with missile attacks on Israel. The strikes marked the start of what Iranian state media called 'The Hard Retaliation.
Read moreQ: What attracts investors to PED as an energy stock?
A: PED operates in the oil and gas sector, which historically benefits from rising commodity prices and demand fluctuations. Some investors are drawn to its low price point for high growth potential, though they should be cautious of inherent energy market volatility.
Q: Why might BITF be of interest to cryptocurrency enthusiasts?
A: BITF focuses on cryptocurrency mining, providing exposure to bitcoin's performance without directly investing in the digital asset. Investors should note the stock's sensitivity to bitcoin price swings and regulatory changes in the cryptocurrency sector.
Q: How does DNN benefit from its involvement in uranium mining?
A: DNN is involved in uranium extraction, a key component for nuclear energy. Interest in clean energy solutions can drive demand for uranium, potentially boosting DNN's prospects. However, geopolitical and environmental concerns may impact this market.
Q: What features of SENS appeal to tech investors?
A: SENS develops glucose monitoring systems, tapping into the growing health-tech niche. The global rise in diabetes management solutions presents growth opportunities, although competition and regulatory hurdles present risks.
Q: Are ATOS's developments in biotechnology promising for investors?
A: ATOS is involved in breast cancer research, offering potentially high-reward investment due to medical breakthroughs. However, drug approval processes in biotech are lengthy and uncertain, elevating associated risks.
Q: What economic factors impact ZOM's role in veterinary pharmaceuticals?
A: ZOM develops animal diagnostics and products, benefiting from increasing pet ownership and spending on animal healthcare. Yet, new product launches and competitive pressures can affect profitability.